Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti –VEGF Drug Type for 1 Year in the IRIS Registry

The purpose of this study is to compare real-world visual acuity (VA) in patients with neovascular age-related macular degeneration (nAMD) treated with a single anti –vascular endothelial growth factor (VEGF) drug monotherapy for 1 year from the American Academy of Ophthalmology (AAO) Intelligent Research in Sight (IRIS) Registry.

http://www.aaojournal.org/article/S0161-6420(17)31946-2/fulltext?rss=yes

Source: Ophthalmology - November 13, 2017 Category: Opthalmology Authors: Prethy Rao, Flora Lum, Kevin Wood, Craig Salman, Bhavya Burugapalli, Rebecca Hall, Sukhminder Singh, David W. Parke, George A. Williams Source Type: research

More News: Academies | Age-Related Macular Degeneration (AMD) | Eyes | Opthalmology | Study